Explore

Trendline Trendline
ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment

ABION's ABN202 Shows Promise in Overcoming Resistance in Cancer Treatment
Trendline Trendline
Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies

Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies

Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition
Trendline Trendline
Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors
Trendline Trendline
Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast